Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke Sells 22,000 Shares

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $71.52, for a total value of $1,573,440.00. Following the transaction, the chairman now directly owns 79,634 shares in the company, valued at $5,695,423.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ionis Pharmaceuticals stock traded down $4.30 during mid-day trading on Thursday, reaching $67.85. 1,113,623 shares of the company traded hands, compared to its average volume of 1,190,039. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.01 and a quick ratio of 9.93. The firm’s 50 day moving average price is $66.47 and its 200 day moving average price is $68.87. The firm has a market capitalization of $9.98 billion, a price-to-earnings ratio of 22.92 and a beta of 2.07. Ionis Pharmaceuticals Inc has a 52-week low of $43.27 and a 52-week high of $86.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.26. The business had revenue of $164.00 million for the quarter, compared to the consensus estimate of $145.31 million. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. The company’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.29) EPS. On average, sell-side analysts anticipate that Ionis Pharmaceuticals Inc will post -0.07 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Natixis grew its position in shares of Ionis Pharmaceuticals by 316.0% in the 2nd quarter. Natixis now owns 99,891 shares of the company’s stock worth $6,420,000 after buying an additional 75,880 shares during the period. Vestmark Advisory Solutions Inc. grew its position in Ionis Pharmaceuticals by 1.1% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 24,373 shares of the company’s stock valued at $1,566,000 after purchasing an additional 266 shares during the last quarter. International Biotechnology Trust PLC grew its position in Ionis Pharmaceuticals by 73.3% during the 2nd quarter. International Biotechnology Trust PLC now owns 82,781 shares of the company’s stock valued at $5,320,000 after purchasing an additional 35,000 shares during the last quarter. UBS Group AG grew its position in Ionis Pharmaceuticals by 39.0% during the 2nd quarter. UBS Group AG now owns 145,479 shares of the company’s stock valued at $9,349,000 after purchasing an additional 40,817 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. grew its position in Ionis Pharmaceuticals by 1.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,084 shares of the company’s stock valued at $1,040,000 after purchasing an additional 154 shares during the last quarter. 85.36% of the stock is currently owned by institutional investors and hedge funds.

IONS has been the subject of a number of research analyst reports. Piper Jaffray Companies set a $75.00 price target on Ionis Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, May 24th. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Evercore ISI set a $76.00 price objective on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald reissued a “hold” rating and set a $68.00 price objective on shares of Ionis Pharmaceuticals in a research report on Wednesday, April 24th. Finally, BMO Capital Markets reduced their price objective on shares of Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 24th. Nine investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Ionis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $67.78.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

See Also: Overbought

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.